Grignani F
Crit Rev Oncol Hematol. 1985;4(1):31-66.
Chronic myelocytic leukemia (CML) is a well-known myeloproliferative disorder, with typical clinical and hematological features, which develops into a lethal blastic crisis within an average of 4 years. In the last few years much has been learned about the cell responsible for the leukemic deviation, chromosomal abnormalities both in chronic phase and in blastic transformation, biochemical and cytochemical behavior of leukemic cells, and the immunology of the disease. On the contrary, polychemotherapy has brought but little progress in CML treatment. However, thorough research on prognostic factors at the onset of the disorder allows a more rational approach to the treatment, and in the near future interesting progress in bone marrow transplantation is to be expected. Also, monoclonal antibody techniques will reveal further knowledge on the origin and differentiation of leukemic cells and the relationship between the chronic phase and the blastic deviation.
慢性粒细胞白血病（CML）是一种众所周知的骨髓增殖性疾病，具有典型的临床和血液学特征，平均4年内会发展为致命的急变期。在过去几年中，人们对导致白血病偏离的细胞、慢性期和急变期的染色体异常、白血病细胞的生化和细胞化学行为以及该疾病的免疫学有了很多了解。相反，多药化疗在CML治疗方面进展甚微。然而，对疾病发病时预后因素的深入研究使得治疗方法更加合理，并且在不久的将来有望在骨髓移植方面取得有趣的进展。此外，单克隆抗体技术将揭示关于白血病细胞起源和分化以及慢性期与急变期之间关系的更多知识。
